Pretreatment with chlormadinone acetate eliminates testosterone surge induced by a luteinizing-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate.

Abstract

We investigated the efficacy of 2-week and 4-week pretreatments with 100 mg/day chlormadinone acetate (CMA) to prevent the flare reaction induced by luteinizing-hormone-releasing hormone (LHRH) in patients with metastatic carcinoma of the prostate. CMA lead-in therapy suppressed bone pain and serum levels of luteinizing hormone, testosterone and prostate-specific antigen levels. CMA therapy also suppressed the transient increases in these levels associated with the initiation of therapy. The 4-week regimen appeared to be more effective than the 2-week regimen.

• Authors: K Yoshida, S Takeuchi
• Journal: European urology (Eur Urol) Vol. 27 Issue 3 Pg. 187-91 ( 1995) ISSN: 0302-2838 [Print] Switzerland
• PMID: 7541358 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Chlormadinone Acetate
• Gonadotropin-Releasing Hormone
• Testosterone
• Luteinizing Hormone
• Prostate-Specific Antigen

Topics

• Administration, Oral
• Aged
• Aged, 80 and over
• Carcinoma (blood, prevention & control)
• Chlormadinone Acetate (therapeutic use)
• Disease Progression
• Gonadotropin-Releasing Hormone (adverse effects)
• Humans
• Injections, Subcutaneous
• Luteinizing Hormone (blood, drug effects)
• Male
• Middle Aged
• Premedication
• Prostate-Specific Antigen (blood, drug effects)
• Prostatic Neoplasms (blood, prevention & control)
• Testosterone (blood)